INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

A Comprehensive Review on Ondansetron Orodispersible Tablets

Rani Ade*[1], Vaishnavi Tajne[2], Dr. Avinash Jiddewar[3], Pradip More[4]

[1,2,3]NSPM College of Pharmacy, Darwha, Yavatmal, Maharashtra, India.
[4]M. Pharm, Department of Pharmaceutical Chemistry Kishoritai Bhoyar College of Pharmacy.

ARTICLE INFO

Published: 15 Dec 2025
Keywords:
Ondansetron ODTs; Antiemetic; Rapid onset; 5-HT3 antagonist; Patient compliance
DOI:
10.5281/zenodo.17934205

ABSTRACT

Ondansetron orodispersible tablets (ODTs) are an advanced antiemetic formulation that rapidly disintegrates in the mouth, providing faster absorption and earlier onset of action than conventional tablets—an important advantage in managing chemotherapy- and postoperative-induced nausea and vomiting. Use of superdisintegrants and modern manufacturing techniques has improved disintegration time, taste masking, and mechanical strength. Pharmacokinetic and clinical studies show that ondansetron ODTs are bioequivalent to standard oral tablets while achieving peak plasma levels 30–40% faster, resulting in effective and timely 5-HT3 receptor blockade. They demonstrate comparable or superior efficacy with better patient compliance across adult, pediatric, and special populations. Safety concerns, particularly dose-dependent QT interval prolongation, require careful dosing and monitoring in high-risk groups, reflected in updated regulatory guidelines. The global market for ODTs is expanding due to geriatric and pediatric demand, although cost and accessibility remain challenges. Future developments aim to improve stability and large-scale manufacturing, with emerging technologies such as 3D printing, nanotechnology, AI-driven formulation design, and combination ODTs expected to further enhance personalized and patient-centered antiemetic therapy.

INTRODUCTION

Ondansetron is a common selective 5-HT3 receptor antagonist that is commonly used in the prevention of nausea and vomiting in chemotherapy, radiotherapy, and surgery. (1)It helps to manage acute and delayed emesis by inhibiting serotonin in the chemoreceptor trigger zone and the gastrointestinal tract, leading to better patient comfort and adherence to treatment. Clinical studies have well supported its high therapeutic efficacy. (2)

Designing ondansetron in the form of an orodispersible tablet (ODT) offers significant

***Corresponding Author:** Rani Ade
Address: *NSPM College of Pharmacy, Darwha, Yavatmal, Maharashtra, India.*
Email ✉: raniade296@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

benefits compared to standard tablets and injections. ODTs are rapidly dissolved in the mouth without the need of water and are therefore providing a faster benefit of action along with ease of administration to the patients who have a hard time swallowing, particularly during nausea. This route of administration enhances the convenience and compliance of both pediatric and geriatric and dysphagic patients. (3)

Special attention should be devoted to ondansetron ODTs in order to demonstrate the latest developments in the field of formulation, bioavailability, clinical performance, and safety issues. It also aids in evaluating a breakthrough in excipients, manufacturing technologies, and patient-centered design, which could be of benefit in streamlining the antiemetic therapy and enhancing patient compliance. (4)

Advances in Formulation Technology

Recent Excipients and Superdisintegrants Improving Tablet Disintegration Time and Mechanical Strength

Superdisintegrants are very crucial in ondansetron ODT formulations, as they are critical in facilitating quick break-up of the tablet without compromising the mechanical strength. Sodium starch glycolate (SSG) and croscarmellose salt sodium (CCS) are widely used and when combined take a lot shorter period of about 19 seconds to disintegrate compared to 35 to 60 seconds of conventional tablets. This is due to the synergistic effect of SSG swelling fast and CCS wicking the capillaries, and thus destabilising the tablet matrix. This is because crospovidone is another good super disintegrant and performs well when combined, and the disintegration rates are very fast 3-5 seconds in vitro and the same in vivo. At appropriate concentrations (4 to 10 percent w/w) with appropriate diluents e.g. MCC, and dry lactose, these superdisintegrants are capable of offering good hardness (8 to 15 kP) and low friability (less than 1 percent w/w) with the porosity required to ensure rapid uptake of water and rapid disintegration in the mouth.(5–7)

Novel Manufacturing Approaches: Spray Drying, Lyophilization, and Hot-Melt Extrusion

Lyophilization (freeze-drying) is a modern technique applied to create ondansetron ODTs, particularly, heat sensitive medications. The procedure freezes the drug excipient mixture at a temperature lower than its eutectic point and removes moisture to approximately 4 per cent producing highly porous tablets that dissolve in less than 5 seconds (because of its high surface area and quick saliva penetration). lyophilized ondansetron ODTs dissolve much faster (t 90) than standard tablets (t 90). Nonetheless, the method is associated with several disadvantages, such as expensive nature, laborious nature, brittle nature of the tablets leading to special packaging, and sensitivity to moisture that may compromise its stability. (8–10)

Spray drying is a less expensive substitute to lyophilization to make porous powder matrices that are utilized in the ondansetron ODTs. Under this process, a solution of drug-excipient mixture with gelatin and mannitol is atomized in hot air to make a fine powder in a porous form within a short period. This powder is then mixed and pressed into tablet form which dissolves and disintegrates faster than pressed tablet as they have porosity within them. Spray drying compared to lyophilization has shorter processing times, reduced equipment cost, and can be easily scaled to industrial scale, as well as giving similar rapid dissolution and disintegration characteristics. (8,10)

Hot-melt extrusion (HME) is a recent technique of producing ondansetron ODTs where heat and pressure are applied to a polymer mixture of drugs that may include water soluble PEG and methanol then extruded through dies to create porous structure matrices that are subsequently heated and sliced into tablets. It produces amorphous or partially crystalline drug phases which significantly enhance dissolution, solubility and bioavailability. It is also able to deliver specific drug loading, uniform distribution, and stronger pills with less friability, and the final ODTs can be managed and stored at normal packaging conditions. (11)

Taste Masking Innovations Enhancing Patient Acceptability

Ondansetron hydrochloride (and especially the dihydrate form) has a highly bitter and irritating taste, which greatly undermines patient acceptability of orodispersible tablets. To overcome this formulation issue and enhance patient adherence, several strategies of taste-masking have been formulated to help overcome this issue, particularly in pediatric groups. (12,13)

Polymer mixing especially with aminoalkyl methacrylate types like Eudragit EPO is the go to way to hide ondansetron's bitter taste in ODTs. Instead of just sticking together, they form ionic bonds; this builds a shield around the drug so it will not hit your tongue's sensors early. That barrier holds back release in the mouth but breaks down quickly once it hits stomach acid. In real human tests using a 1-to-3 mix of drug and polymer, people barely noticed any bitterness - the rating dropped from 3 straight down to under half, even hitting zero after about fifteen minutes. Other materials, say Tulsion 335, work much the same when used at those levels - not only cutting off bad flavor but also keeping tablets dissolving fast, which means little or no yucky taste plus quick relief.(12,14)

Alkalizing stuff changes how things taste by shifting mouth acidity. Ondansetron does not mix well with water when the pH goes up, so adding compounds like baking soda or chalk boosts the pH right where you taste, slowing down how fast the medicine breaks apart - this hides the nasty flavor. These additives usually make up between 2 and 20 percent of the pill's weight. As the tablet falls apart in spit, the ingredient holds the pH high nearby, keeping the crushed-up medicine solid till it is gulped into the stomach; there, acid kicks in and lets the drug dissolve. (15)

Saccharides used as sweeteners make medicines more agreeable by improving how they smell and taste. Instead of sugar, makers often pick mannitol, sorbitol, xylitol, or glucose each added between 0.5% and 10% by weight - to give a nice initial flavor that covers up lingering sourness. On top of that, flavors like mint or strawberry, either natural or man-made, go in at around 0.5% to 2%, helping the dose feel easier to take. Besides taste, these ingredients help the tablet break apart fast since they attract water and let it seep quickly into the structure. (5,13)

Direct coating methods are new ways to wrap medicine particles in a polymer layer right away after that, they are blended with helper granules before getting pressed into tablets. These coatings keep the pill strong but stop bad tastes from spreading around the mouth. Because of this, regular machines can still be used for making and packing them. Instead of just one trick, experts now mix polymers, pH adjusters, or flavor-friendly additives all working together differently depending on the case - to make ondansetron fast-dissolve tablets easier to take across different groups of people without slowing down how

quickly they break apart or reducing their healing effect. (9,14)

Pharmacokinetic and Pharmacodynamic Advances

Updated Bioavailability Data Comparing ODT to Conventional Oral and Injectable Forms

Ondansetron orodispersible tablets are around 60% bioavailable - ranging from 55 to 70%. That's pretty much the same as regular pills you swallow. What sets them apart is how quickly they get into your system. Normal tablets usually hit max levels in blood after roughly 90 minutes. But better versions of these fast-dissolving ones do it in just about an hour - so they work one-third quicker. Why? They break down super-fast in your mouth, like in under five seconds. Also, some of the drug might soak in right through the lining of your mouth. Because of this, your gut doesn't have to handle everything, which normally takes more time. Bioequivalence tests - like ones done with healthy young men from China - showed matching results between different ondansetron ODT versions; the 90% CI for peak levels and total exposure stayed inside the standard 80–125% window, proving they work alike. Blood level patterns lined up well across people, where full-dose absorption ($AUC_{0–\infty}$) ranged near 287 to 293 ng·h/mL while highest concentrations (Cmax) hit about 33 to 39 ng/mL when taking 8 mg dissolvable tablets. (16–18)

Injectable vs. pill forms: how ondansetron acts in the body looks much alike whether swallowed, shot into muscle, or given through a vein - muscle and vein methods give nearly the same levels in blood as swallowing it. Instead of shots, dissolving tablets skip needles, can be taken alone, also kick in fast even without an IV line. Suppositories go in through the rectum - they get about 60% into the system like regular pills do - but take longer to absorb, clear out slower because they release gradually.

Special Populations: In older people who are healthy, the body absorbs a bit more of the drug by mouth - about 65% - while the breakdown time stretches to roughly 5 hours, compared to 3–3.3 in younger adults; yet, this change doesn't really matter in practice. On the flip side, those with cancer take in way more of the medicine orally (85–87%) versus healthy folks (50–70%), probably because their liver processing shifts thanks to illness or chemo drugs. Because absorption varies so much, adjusting doses becomes key when treating nausea in cancer cases. (19)

Improvements in Onset of Action and Duration of Efficacy

Rapid Onset Advantages: Quick-absorbing ondansetron ODTs start working faster, which helps stop sudden nausea before it gets worse. Because they dissolve fast and get partly absorbed through mouth tissues, these pills hit effective doses quicker than regular ones. Like sublingual versions, ODTs can reach max concentration in about 10–15 minutes - way faster than the 90-minute wait for traditional tablets. That speed makes a real difference when treating nausea after surgery, right as people are waking up. (19)

Duration of Efficacy: Ondansetron ODTs last around 3 to 4 hours, just like other types. Yet they hit peak levels quicker, so medicine kicks in fast - right when it's needed most after surgery or chemo-related sickness starts. Since nausea checks happen mainly in the first 6 hours, that quick action helps block vomiting better. During these initial 6 hours, ondansetron fully controls symptoms in roughly 52.5% of people by itself - or up to 87.5% if used alongside dexamethasone instead. (20,21)

Pharmacodynamic Implications in Chemotherapy-Induced and Postoperative Nausea

5-HT3 Receptor Antagonism Mechanism: Ondansetron works by shutting down specific 5-HT$_3$ receptors - this stops serotonin from acting in key areas like the brain's trigger zone and gut nerves, hitting the main routes behind nausea caused by chemo or operations. The drug locks onto these sites quickly and strongly, filling them up soon after dosing, so relief kicks in fast. (17,22)

Chemotherapy-Induced Nausea and Vomiting (CINV): Ondansetron works well against nausea and vomiting right after chemo, plus symptoms that pop up later. For medium-risk treatments, around half to two-thirds of patients feel fully relieved. When strong triggers are involved, nearly three out of four still get queasy if they only take this drug. But pairing it with dexamethasone boosts relief - up to 87 or 92 percent then report no issues. One big perk of the dissolvable type? It kicks in fast, blocking gut signals before sickness starts, especially useful when treatment begins. (21–23)

Postoperative Nausea and Vomiting (PONV) Efficacy: Ondansetron works well to stop nausea after surgery by targeting specific brain and gut signals tied to anesthesia and operation stress. On its own, using doses from 4 to 16 mg, about half of patients feel completely fine during the day following procedure. Team it up with dexamethasone, though, and that number jumps - up to nine out of ten people stay symptom-free, especially right when risk peaks, within six hours post-op. Against palonosetron, this drug wins early on; at eight milligrams, fewer issues pop up in the first six hours. Yet, palonosetron lasts longer, covering symptoms better from day one onward thanks to slower clearance. Because it kicks in fast, ondansetron fits best when quick protection matters most. (24)

Clinical Implications of Pharmacokinetic-Pharmacodynamic Relationships: The fast start of effect with ondansetron ODTs - unlike regular pills - lines up medicine levels better with when nausea hits hardest, right after waking from anesthesia or once chemo starts. Because it kicks in quicker, patients often feel better sooner, need fewer backup drugs, and report feeling more comfortable throughout treatment, whether they're recovering from surgery or getting cancer care.

Clinical Evidence and Therapeutic Effectiveness

Latest Clinical Trial Outcomes on Efficacy in Adult, Pediatric, and Special Populations

Pediatric Efficacy in Chemotherapy-Induced Nausea and Vomiting (CINV):

Ondansetron ODTs work well for kids with chemo-related nausea. During high-risk treatment, IV ondansetron gave full control in 56% of cases; switching from IV to pills dropped it to 42%. For medium-risk chemo, taking ondansetron by mouth along with dexamethasone led to success in 71–73% of patients. All things considered, dissolvable ondansetron combined with steroid meds offers solid prevention against vomiting in young ones .(25)

Pediatric Efficacy in Postoperative Nausea and Vomiting (PONV):

Big studies involving 1,469 kids aged 2 to 12 found that giving ondansetron - either 0.1 mg/kg or 4 mg through a vein - really cut down nausea after surgery. During eye alignment operations, using dissolvable tablets before the procedure (4–8 mg) led to full relief in 76 out of 100 cases, compared to just 16 when fake treatment was used.

Kids getting the real tablet needed emergency meds much less often - only 11% versus 55%. Also, serious vomiting happened way less: 18% had it, unlike 61% without the drug. All children handled the melt-in-mouth form fine, plus there were zero hospital stays due to sickness. (26)

Adult Efficacy in Acute Gastroenteritis:

New reviews show ondansetron works better than domperidone or metoclopramide when treating sudden stomach virus vomiting in adults. Six hours after taking it, 80% of people using ondansetron stopped throwing up - compared to 72.5% with domperidone and 67.5% with metoclopramide. After a full day, results got even clearer: 92.5% on ondansetron had no more vomiting, while just 82.5% improved on domperidone and 77.5% on metoclopramide - with stats confirming this gap mattered. In kids between 3 months and 5 years old, nearly everyone - 95% - on ondansetron quit vomiting within 24 hours; only about 85.5% did so on domperidone. Overall, these numbers suggest ondansetron beats older anti-nausea drugs tied to dopamine control. (27)

Elderly Population:

Early tests in healthy older people saw just minor drops in how fast the body cleared the drug, along with tiny rises in how long it stayed active - though results varied a lot, matching what's seen in younger adults. Studies for preventing chemo nausea also showed ondansetron worked just as well and was equally safe in younger patients under 65 compared to those 65 and up. Overall, this means the dissolving tablet form can be used across ages without changing the dose .(25)

Special Paediatric Populations (Younger Infants):

A population study of 428 people aged 1 month to 44 years found kids and teens usually have about the same ondansetron levels as adults. Infants from 1 to 4 months are different - clearance per body weight is roughly 30% lower, so the drug stays longer, around 6.7 hours instead of 2.9 in those 5–24 months or 3–12 years old. Still, since babies under six months get just one dose for nausea after surgery, the slower removal doesn't really matter in practice.(27,28)

Comparative Effectiveness with Other Antiemetic Formulations

Ondansetron versus Domperidone and Metoclopramide:

A review of 19 child-focused stomach illness studies found ondansetron worked way better than a dummy pill at halting throw-up; meanwhile, domperidone and metoclopramide helped just a little, but not enough to matter. When lined up by results: ondansetron beat both others. The reason it performs best? It blocks 5-HT_3 receptors precisely - this shuts down nausea signals fast. In contrast, drugs hitting dopamine aren't as focused - one may cause movement issues, another raises heart worries. (27,28)

Ondansetron Orodispersible Film versus Intravenous Ondansetron:

A recent test compared two forms of ondansetron used during gynecologic keyhole surgery - one a dissolving mouth film, the other given through a vein - finding they work about equally well. During the initial six hours, patients using the 8 mg oral strip vomited less often when measured against those getting the drug via IV ($p=0.044$) or dummy treatment ($p=0.002$). From hour zero to day one, both film versions - 4 mg and 8 mg - did better than fake pills. Nausea after surgery hit 58% in the sugar-pill group, dropped to 46.5% with IV

meds, stood at 51.2% for low-dose strips, yet fell further to 34.9% among high-dose strip users. Results suggest the melt-in-mouth version works just as good, might even beat the needle form early on, plus it's easier to use and cheaper. (29)

Ondansetron versus Palonosetron (Second-Generation 5-HT3 Antagonist):

Research shows ondansetron (8 mg) works better than palonosetron early after surgery - within 6 hours - cutting vomiting nearly completely versus a small number with palonosetron (0 vs. 0.16; $p<0.001$). After that window, things shift. Palonosetron takes over from 6 to 72 hours thanks to its longer stay in the body - around 40 hours, far outpacing ondansetron's short span of just 3–4 hours. So, pick ondansetron ODT when you need fast protection right after an operation. Go for palonosetron if guarding against later nausea matters most .(24)

Patient Reported Outcomes Focusing on Compliance and Satisfaction

Taste Acceptability and Medication Willingness:

A trial led by Cohen and team looked at kids 5 to 11 having adenotonsillectomy; it found that most liked using ondansetron ODTs. Around 87% thought the tablets tasted fine or felt okay in their mouths, while nearly the same number said they'd use them again if needed. Even though ondansetron is normally bitter, about 9 out of 10 still called the dissolving tablet "pleasant." True, some preferred a dummy pill instead - still, hardly anyone refused to take it, which shows today's flavor-hiding methods really work. (30,31)

Comparison of Flavor Preferences:

More studies into kid-friendly meds showed taste likes change with age. Kids below 12 tended to favor dissolvable tablets instead of liquid syrup - especially those aged 4–8, who liked strawberry tablets more than minty syrups. For children above 5, ondansetron tablets that melt in the mouth seem well liked, provided they're flavored right .(30)

Overall Patient Satisfaction in Postoperative Settings:

In a forward-looking study where people got either dissolvable ondansetron films or IV meds, one thing they checked was how happy patients felt - this score turned out better for those using the melt-in-mouth version versus both the IV and dummy treatments. Folks directly said the film worked well for them, hinting that swallowing medicine might feel more natural than getting it through a vein. Other checks showed folks started eating sooner after taking the film, needed less pain relief afterward, while side issues like lightheadedness or head pressure stayed low no matter which ondansetron type they used. (29)

Medication Compliance Implications:

Ondansetron ODTs make sticking to treatment much easier - especially for people with cancer on long-lasting nausea meds. No need for water or shots, plus they taste better, which clears big hurdles compared to pills or jabs. For kids and seniors, this matters a lot since many struggle with bad flavors or swallowing problems. Research finds folks stick with ODTs more often - and feel happier using them - which means steadier protection against sickness and day-to-day life feels smoother. (28,32)

Safety Profile Across Populations:

Ondansetron ODTs tend to cause few side effects, working safely in kids, adults, or older people during tests. Still, longer QT intervals can happen more with higher doses - yet this stays under

control when used normally for nausea after surgery or chemo. Even real-world reports plus large study reviews agree: risks are low, just occasional headaches, slight constipation, or short-lived lightheadedness popping up now and then .(27,32)

Safety Profile and Risk Management

Updated Safety Data Including QT Prolongation Risk and Other Adverse Effects

QT Interval Prolongation Dose-Dependent Phenomenon:

The biggest heart-related worry with ondansetron is how it can stretch the QT interval, especially when given in higher doses - this showed up clearly in a strict FDA-required test run by GSK. Instead of just adding numbers together, look at this: giving 8 mg through an IV to 58 healthy people led to a small rise in QTcF by 5.8 ms, with the upper limit hitting 7.8 ms, which experts see as minimal danger. But things shifted sharply when they used the old 32 mg IV dose - it pushed the QTcF up by nearly 19.6 ms, topping out at 21.5 ms, signaling a much stronger chance of irregular heartbeat. Using math models, scientists estimated that a 16 mg IV dose would only bump QTcF by around 9.1 ms, maxing out near 11.2 ms - that's within a more acceptable zone. Because of these findings, authorities like the FDA and EMA now cap the one-time IV dose at 16 mg worldwide. (33,34)

QT Prolongation Risk in Special Populations:

As people get older, they face higher chances of heart rhythm issues from ondsensetron - this happens due to natural heart wear like stiffer tissue, scarring, and shifts in how electric signals move through the heart. On top of that, many seniors take several meds at once, which stacks up the danger. The medicine interacts badly with around 161 others that also stretch the QT interval, such as mental health drugs like haloperidol or pimozide, some antibiotics including ciprofloxacin, heartbeat regulators like amiodarone or disopyramide, similar nausea blockers like granisetron, along with mood medications such as sertraline or duloxetine. Since every one of these alone can delay heart recovery time after a beat, using them together makes the effect stronger, raising the threat of severe irregular rhythms - especially a type called Torsades de Pointes.(32,35)

Electrolyte Abnormalities and Associated Hypokalaemia:

A uncommon yet dangerous side effect of ondansetron is low body salts, particularly potassium dropping too low. Instead of normal function, this drug triggers kidney pathways that push out potassium - by weakening NKCC2 in the loop of Henle while sending more sodium down the tube, boosting ROMK-driven potassium release in the collecting duct at the same time. Because both shifts happen together, large amounts of potassium exit through urine. One example showed a 45-year-old person recovering from stroke falling into deep potassium shortage (2.5 mEq/L) only 48 hours after starting intravenous ondansetron; even adding supplements didn't help until the medication got stopped, then levels bounced back to normal in under two days. Low potassium might cause QT changes, ST shifts, U wave signs, flatter T-waves - also raises chance of Torsades. A few rare instances of low magnesium showed alike heart issues. (34)

Other Adverse Effects from Pharmacovigilance Data:

A FAERS review from 2014 to 2024 looked at 9,413 cases tied to ondansetron - revealing key safety concerns. Most prominent? Issues linked to birth defects and inherited conditions (n=4,725; ROR 30.33), mainly because of fetal heart problems and drug use during pregnancy. When it comes to pregnancy complications (n=1,277; ROR 5.53), there's a link - but no proof of direct cause. Fresh red flags popped up: infections (ROR 1.24), mental health issues (ROR 1.14), plus changes in body chemistry (ROR 1.29). Guys tended to mention birth defects in the heart or injuries more often - girls, on the other hand, brought up issues tied to pregnancy or mood struggles way more. Classic side effects like headaches, stomach troubles, and low energy still popped up the most .(36)

Hepatic Impairment Related Safety Considerations:

In people with serious liver problems (Child-Pugh score ≥7), ondansetron leaves the body much more slowly half-life jumps to 15–32 hours instead of the usual 3–4. Because the liver can't process it well, nearly all the drug gets into the bloodstream, so levels build up fast. That higher exposure raises chances of side effects tied to dosage, like heart rhythm issues such as QT prolonging. For this reason, rules clearly state those with medium to severe liver trouble shouldn't take more than 8 mg of ondansetron per day. (25)

Risk Mitigation Strategies in Vulnerable Populations

Pre-Treatment Assessment and Electrolyte Correction:

Before giving ondansetron to at-risk people, doctors should check how much danger there is. Groups that oversee medicine say everyone should get a heart test first - especially older adults or anyone with known heart issues. Blood tests for potassium and magnesium levels are needed ahead of time; if results show low values (<3.5 mEq/L for potassium, <1.7 mg/dL for magnesium), fix them before starting the drug. Getting these imbalances under control cuts down the chance of dangerous heartbeat changes. (37)

Dose Optimization in Special Populations:

Elderly Patients (≥65 years): Older people absorb ondansetron just as well as younger ones when taking it by mouth - so no need to change the dose for seniors using dissolvable tablets. Trials show results and side effects are about the same in folks over 65 compared to younger users. Still, doctors should check heart health and mineral levels before starting treatment because aging affects body functions. (34)

Patients with Hepatic Impairment: In cases of moderate or serious liver issues, ondansetron shouldn't go above 8 mg per day just one dose at that level. For those with slight liver problems, there's no need to change the usual amount. (17)

Patients with Renal Impairment: Unlike liver problems, kidney issues barely affect how the body handles ondansetron. For people with poor kidney function - even those on dialysis - there's no need to change the dose, timing, or way the drug is given.

Pediatric Populations: In children receiving chemotherapy, body surface area-based dosing (typically 0.1-0.15 mg/kg per dose up to 4 mg maximum) appropriately adjusts systemic exposure and normalizes drug accumulation. (25)

Concurrent Medication Management:

Ondansetron needs a full check of your meds to spot anything that could stretch the QT interval. You must skip it if using apomorphine it can cause

serious drops in blood pressure or fainting. Also avoid combining it with drugs known to greatly extend QT time, like pimozide, some fluoroquinolones, or antiarrhythmics. When those medicines are necessary, swapping to another nausea treatment works better - try metoclopramide or domperidone when chemo isn't involved. With antidepressants such as SSRIs, TCAs, or SNRIs, keep an eye out for signs of serotonin overload restlessness, mental fog, fast pulse, stiff muscles even though ondansetron carries much less danger here compared to other 5-HT3 blockers. (34,38)

ECG Monitoring Protocols:

Keep watching the heart closely when dealing with these risky cases: first, people whose body salts are off and need fixing; next, folks struggling with a weak heart pump; also, anyone showing very slow heartbeat - below 50 beats per minute; then, those on drugs that stretch the heart's electrical timing at the same time; finally, older adults aged 75 or more getting cancer treatment. Checking ECGs now and again helps catch rising QT issues early, well before rhythm problems show up. (34,38)

Serotonin Syndrome Risk Mitigation:

Even though ondansetron carries a smaller chance of serotonin syndrome compared to similar drugs, mixing it with other mood-affecting meds needs careful watch. Doctors ought to tell people taking this drug what to look out for like restlessness, disorientation, fast or uneven pulse, stiff muscles, sudden high body heat and urge them to speak up fast if any show up. (39)

Regulatory Considerations Impacting Approval and Clinical Use

FDA Regulatory Guidance and Bioequivalence Standards:

The FDA's 2024 rules set bioequivalence standards for ondansetron ODTs and oral strips. Oral films need live testing where Cmax and AUC stay between 80–125% (90% CI). Testing happens by putting the strip on the tongue - no water used - and following exact blood sample timing. When higher doses aren't tested directly, waivers may apply if lab results match closely across strengths and ingredients scale evenly. With this step-by-step method, several dose forms can get approved using just one live test along with solid dissolve checks .(40)

EMA/CHMP Regulatory Framework:

The European Medicines Agency oversees ondansetron mouth-dissolving forms using existing CHMP guidelines. While some countries approved these versions locally, others followed a shared EU process. Instead of separate checks, EMA uses tests like those from the FDA - so quality stays consistent wherever it's used .(41)

Dose Restrictions and Labeling Requirements:

After safety concerns around heart rhythm, agencies like the FDA and EMA changed ondansetron's label rules. Now, one IV shot can't go above 16 mg. But pills - also ODT forms - stay the same: up to 32 mg per day, split into doses. Warnings are required now - one covers QT prolongation risks; another says no use in people born with long QT syndrome. Doctors should also watch out when giving it to those with existing heart issues. (40,41)

Post-Marketing Surveillance Requirements:

Government watchdogs keep an eye on ondansetron after it hits the market - no matter the version. Drug makers have to track side effects nonstop, using tools like MedWatch in the U.S., EudraVigilance in Europe, or local Yellow Card

setups. If someone gets a dangerous heart rhythm issue, extreme allergic reaction, or develops Stevens-Johnson syndrome, companies must act fast - report quickly and maybe warn the public. Thanks to this constant follow-up, new risks pop up early, so alerts can go out without delay. (17,36)

Clinical Practice Guidelines from Regulatory Bodies:

The National Comprehensive Cancer Network (NCCN) along with the American Society of Anesthesiologists (ASA) plus some other medical groups have used safety reports from the FDA and EMA to shape their advice - like checking heart health and blood minerals before treatment, watching ECGs closely in risky cases, also skipping high IV doses of ondansetron. Their guidance points out that ondansetron dissolvable pills, which help stop nausea from chemo taken by mouth or sickness after surgery, don't fall under the 16 mg limit set for IV use since they get into the bloodstream more slowly. (34)

Market Trends and Patient-Centric Perspectives

Growing Market Demand for Patient-Friendly Dosage Forms

Global Market Size and Growth Trajectory:

The worldwide ODT market's growing fast - people want easier-to-take meds. Some figures put it at $6.5–10.7B in 2024, jumping to $10.8–29.5B by 2033 or 2034, thanks to steady yearly gains of 8–11%. One study expects a rise from $11.38B in 2025 up to $23.18B by 2032, moving at around 10.7% each year. These solid numbers, way above older pill types, show more countries are choosing simpler, user-focused ODT options. (42,43)

Demographic Drivers of Market Expansion:

More people getting older is pushing up demand for ODTs - especially in rich countries where seniors are growing fast. Since many older folks struggle to swallow pills or take multiple meds, regular tablets don't work well for them. Kids are another big group; they usually hate taking standard tablets or can't handle swallowing them at all. People dealing with mental health issues, brain-related diseases like Parkinson's or Alzheimer's, plus gut problems such as IBD or slow digestion also face trouble using normal medicines - ODTs help here. With swallowing issues affecting roughly 15–22% of older adults living at home and half of those admitted to hospitals, there's strong need for easier options like dissolvable tabs. (42)

Technological Innovation and Patient Preferences:

New ways to make fast-dissolving tablets - like using cool sprays, freeze drying, melted mixes, tiny particles, or printed shapes - are helping turn more medicines into this form. These upgrades help hide bad tastes, keep pills strong, and prevent crumbling. People want meds that go down easily without water - that's pushing use worldwide, no matter how old someone is. Experts say custom treatments are boosting growth too, since doses can be tweaked per person. Thanks to a bigger focus on care that fits patients' lives, companies are spending more cash on perfecting dissolvable tabs. (44)

Regional Market Variations:

North America plus Europe once dominated the ODT scene - solid pharma setups and big health budgets made that possible. Still, Asia Pacific is now surging ahead, fueled by city expansion, better wellness knowledge, a swelling middle segment, along with state-backed homegrown production pushes. In India or China, demand's

climbing fast as more people face long-term illnesses and clinics lean into easier medication methods. Meanwhile, Latin America looks promising too, given upgrades in medical networks and outreach targeting kids and older adults .(42,43)

Role of ODTs in Improving Adherence in Oncology Supportive Care

Medication Adherence and Treatment Compliance:

In cancer treatment support, sticking to chemo plans matters a lot - ondansetron ODTs work better than regular pills here. Since they don't require water, people can take them easily even when feeling sick. Swallowing isn't an issue, which helps when nausea hits hard. They dissolve fast, bringing quicker comfort. Plus, flavor improvements make them easier to accept compared to older versions. (44)

Impact on Patient Quality of Life and Treatment Outcomes:

Chemo often brings nasty nausea plus vomiting - this really takes a toll emotionally. When symptoms hit hard, people might skip doses or stop early, which messes up recovery chances. Ondansetron helps cut down queasiness, particularly the dissolvable kind you don't need water for. Because it kicks in fast, stress around treatment drops off noticeably. Staying consistent with chemo becomes easier when sickness is under control. Research links solid symptom management with better moods and fewer missed sessions. Kids especially benefit - the quick-dissolve tablets feel simpler, cause less fear at dose time. Without needing fluids, swallowing pills isn't an issue anymore. That shift makes care routines smoother, more bearable all around. (22,44)

Adherence in Delayed Emesis Management:

Missing doses is usual when nausea hits later - over a day after chemo. A U.S. cancer doctor group checked records and saw most weren't following rules: nearly all skipped proper meds for this late stage, many used too much ondansetron, while almost everyone missed needed dexamethasone. This happens mostly because patients aren't told clearly they must keep taking pills past the first sickness wave. Fast-dissolve ondansetron tablets make sticking to treatment easier, particularly over several days, since they're simpler to swallow and handle well even when feeling off. (44,45)

Long-Term Cancer Care Adherence:

In cancer care over many chemo rounds, sticking better to treatment with easier-to-take meds gradually boosts how well therapy works. Those juggling several support drugs like anti-nausea, infection-fighting, or immune-boosting pills gain a lot from dissolvable tablets that

don't need water and act fast, especially when dealing with sudden sickness, poor eating, or limits on drinking fluids. (44)

Cost-Effectiveness and Accessibility Issues

Drug Acquisition Cost Comparison:

The launch of generic ondansetron in 2006 made it way more affordable, dropping costs that once ran over fivefold above metoclopramides. These days, the WHO sees this drug as a key low-cost treatment option. Even now, orally disintegrating tablets still carry a much steeper price tag than regular pills - mainly because they need advanced production steps like freeze-drying and flavor control. For instance, a month's worth of 4-mg standard tablets runs between $9.50 and $31.40; meanwhile, the same dose in ODT form hits

$44.60 to $46.10 - that's nearly 4.7 to 4.8 times pricier. In similar fashion, 8-mg traditional tablets range from $14.90 up to $35.70, but their fast-dissolve versions go for $51.40 to $53.20, roughly 3.6 to 3.8 times more. (46,47)

Total Cost of Care and Economic Efficiency:

Once you add up everything - staff hours, extra meds, dealing with sudden symptoms - ondansetron ends up costing less than the cheaper dopamine blockers. Even though it first seemed pricier, later data found that each fully helped patient ran just 2.43 to 2.34 times more in round one, dropping to 1.82 down to 1.36 by the third cycle because fewer backups were needed. One look at France's numbers shows ondansetron came out ahead at 190.43 FF compared to metoclopramide's 227.85 FF, adding only 113.38 FF for every new person getting full relief. In general, doing a better job means spending less on emergency drugs and using fewer medical supplies. (47,48)

Insurance Plan Barriers and Prior Authorization Requirements:

Even though ondansetron saves money well, insurance rules often block patients from getting it. A 2024 review of U.S. Medicare plans found that most Part D insurers - about 73% - require special approval before covering it; for Medicare Advantage, that jumps to 83%. On top of this, many impose dose caps - around 1 in 5 for both plan types. These hurdles stick around despite the drug being labeled vital and efficient, likely leftover habits from when it cost way more. Jumping through hoops like prior auth can stall therapy by one or two days, making nausea harder to manage and raising the odds of extra medical visits. What's more, what insurers pay for ondansetron, particularly dissolvable tablets, runs roughly twice as much compared to lower out-of-pocket rates available directly. (42)

Orodispersible Tablet Cost-Accessibility Paradox:

A big challenge pops up with ODTs: even though they make taking meds easier and more reliable, their steep price tags block many from getting them - particularly where incomes are lower. Because of this pricing hurdle, clinics and insurers must weigh better care against tight funding, sometimes requiring approvals or limiting coverage, which ends up keeping patients from using these dissolvable tablets. (43)

Global Access and Health Equity Considerations:

In India plus fast-developing areas, cheaper prices alongside better factory output are cutting down on making costs while boosting how affordable they are. Still, North America together with Europe lead in using ODTs, whereas plenty of low-resource zones across Africa and some Asian spots barely get any - though these dissolving tablets clearly help people who can't swallow pills easily or lack clean water. (42,43)

Future Directions for Improved Cost-Effectiveness:

Market watchers say more copycat drugs, better production tech, plus rising output will slowly cut what buyers pay for ODTs over time. On top of that, new uses of 3D printing and tiny-tech in making ODTs could let doses be tailored to individuals - slashing expenses even more. Once price gaps shrink between regular pills and ODTs, people will switch faster, especially kids and older adults who gain the most from how easy these dissolving tabs are. (42,43)

Challenges and Future Research Directions

Stability and Shelf-Life Concerns Specific to ODTs

Moisture-Related Stability Issues:

ODTs struggle with stability because they're full of tiny holes, lack a protective layer, plus react strongly to dampness. Since they attract water from the air, this wetness soaks into ingredients such as mannitol, sorbitol, or lactose, messing up their form. The polymers that hold things together turn mushy when wet, weakening the whole tablet. Water also speeds up the breakdown of ondansetron through reactions triggered by moisture. When exposed to humidity, both strength of the medicine drops - meaning less active ingredient remains - and its shape suffers, getting softer, crumblier, breaking apart faster. Keeping them dry isn't just helpful - it's critical if you want them to last. (49,50)

Critical Relative Humidity Thresholds:

Stability tests reveal ODT ingredients can hit a tipping point with humidity - once crossed, tablets soak up water and break down. Instead of staying stable, fructose-type versions start falling apart fast; at 40°C and 75% RH, they degraded heavily within half a year thanks to their low threshold (64%). On the flip side, those built with mannitol, like Ludiflash®, still broke apart quickly under wet conditions - always under thirty seconds - even after damp storage, proving tougher against moisture. So picking the right filler matters just as much as keeping air dry during storage if you want them lasting. (51)

Impact on Critical Quality Attributes:

Storage dampness changes how fast ODTs break apart, their firmness, crumble rate, dissolve speed, plus even mix of ingredients. When air's dry, pills dry out - getting tougher and taking longer to fall apart because inactive stuff inside re-forms crystals. In moist air, they might get softer at first and split quicker, yet staying there too long could lead them to absorb water fully or stiffen up, which slows breakdown and hurts shelf life. Because these reactions go opposite ways, it's tough to build a tablet that dissolves quickly but still holds up under different wetness levels.

Storage and Packaging Requirements:

Since ODTs react badly to moisture, rules say they need special wraps - usually sealed foil packs with drying beads - to block damp air. Ondansetron tablets on demand dissolve have to stay below 25°C, also avoid steamy spots such as toilets or showers. Even then, staying dry is tough when fridges or AC aren't around, particularly in hot, sticky countries near the equator. (25,52)

Scaling-Up Manufacturing and Quality Control Hurdles

Manufacturing Process Variability and Scale-Up Challenges:

ODT making's harder to ramp up compared to regular pill production. Methods like freeze-drying, spraying liquid into powder, melting then shaping, or pressing take way longer. Freeze-dried pills break apart super quick - just 3 to 5 seconds - but each run takes a full day or even three, churning out just small batches instead of massive volumes; normal machines pump out millions every hour, so this is hundreds of thousands of times slower. Spraying works quicker than freezing, though it's nowhere near standard speed and loses material along the way because of how it runs. (52)

Quality Control Parameter Challenges:

Checking ondansetron ODTs takes more steps than regular pills - it involves timing how fast they

soak up water, absorb moisture, break down inside the body, plus taste testing. Keeping each batch the same is tough since making these dissolving tabs isn't always predictable. One study looked at four brand-name versions and found big gaps in how quickly they got wet, broke apart, or released medicine - even though every one passed India's drug rules. That means just meeting official specs doesn't mean all brands work the same way. (52,53)

Mechanical Strength and Fragility Issues:

Some ODT methods create pills that aren't as strong as regular ones, so they crack easily when moved or shipped. Those made using freeze-drying, molding, or vaporizing tend to be extra delicate - needing special sealed trays instead of normal wraps. Making tougher versions through melting or mist drying works better, yet needs big factory upgrades to match old-school assembly setups. In short, mass-producing these dissolving tablets stays tough since only a handful of makers own the right certified gear for full-size output. (52)

Excipient Supply Chain and Material Variability:

ODT production needs unique inactive ingredients that break down fast - these must have just-right grain sizes, dryness levels, or movement traits during processing. If supplier materials differ even slightly between batches, tablets can turn out uneven unless every shipment gets strict checks before use. On top of this, those special components - like Ludiflash®, Pearlitol Flash®, or BARETab® ODT mixes - are only made by a few companies, so delays or price jumps might happen if one source runs into trouble. (54,55)

Prospects of Combining Ondansetron ODT with Other Antiemetics or Supportive Agents

Ondansetron-Dexamethasone Combination Efficacy:

Clear proof says ondansetron with dexamethasone works way better at stopping sickness than using just one drug. A big study of 318 people getting cisplatin found that taking ondansetron 8 mg two times a day (on days 2 to 4), along with dexamethasone, blocked late-phase vomiting fully in 62% and eased late nausea in 43.7%. That's different from metoclopramide plus dexamethasone, which helped 60% against vomiting and 53.7% against nausea. For those throwing up during the first day, the ondansetron-dexamethasone pair did stronger - 28.6% stayed vomit-free versus only 3.8% ($p<0.05$). Because of these numbers, this mix is now seen as the go-to plan when chemo brings high risk of nausea. (56)

Combination Antiemetic Strategies for PONV:

To prevent nausea after surgery, ondansetron works much better when paired with dexamethasone - other combo approaches beat single-drug treatment too. One big analysis found that patients given both ondansetron and dexamethasone had no symptoms 87.5 to 90% of the time, compared to just half who got only ondansetron if they were at high risk. When palonosetron was used with dexamethasone, sickness rates dropped fast - from 56% down to 23%. The mix of ondansetron and dexamethasone helped, but not quite as much. In general, hitting nausea from two angles - one drug blocking serotonin, another being a steroid - is now seen as the go-to move for people most likely to feel sick after anesthesia. (57)

Development of Ondansetron Combination ODT Tablets:

Fresh studies are testing combo ODTs mixing ondansetron with dexamethasone. Instead of

separate pills, one tablet might do it all - easier to take, fewer missed doses, exact mix every time, plus better taste control across both meds. Still, hurdles pop up - like keeping the drugs from clashing, making sure they dissolve fast even together, and staying stable when humidity or heat hits. To press this into a solid pill without melting down later means picking fillers smartly, balancing disintegration helpers just right, while holding enough toughness so it doesn't crumble. (52)

Adjunctive Agent Combinations:

More studies are looking at mixing ondansetron with extra helpers. First, ginger stuff like gingerols that's known to fight nausea; pairing it with ondansetron might work better by hitting different targets at once. Next, lorazepam - it eases anxiety, which also cuts vomiting risk and this mix is often used when chemo strongly triggers sickness. Then there's aprepitant, which blocks a specific brain pathway tied to later-phase nausea; teaming it up with ondansetron is becoming popular to cover both early and late symptoms. (22,58)

Emerging Formulation Technologies and Personalized Medicine Approaches

3D Printing Technologies for Personalized Ondansetron Dosing:

The origins of 3D printing can be traced back to the work of Hideo Kodama from the Nagoya Municipal Industrial Research Institute, who first demonstrated the creation of a three-dimensional plastic model using a photo-hardening polymer technique. A major advancement occurred in 1984, when Charles Hull, the co-founder of 3D Systems, invented stereolithography (SLA) a groundbreaking process that laid the foundation for modern additive manufacturing technologies. (59)

Nowadays making 3D printed ondansetron ODTs can use FDM this pushes out medicated strands to build tough pills, though the medicine must handle high temps. Another way's SLS it uses a laser to melt powder fast, good for quick models, however particles need tight management. Then there's binder jetting: it squirts fluid into powder, forms tablets in no time, but results are flimsy, often requiring extra steps after. A big issue with every method? They're sluggish one pill takes about 7 to 15 minutes, much slower than regular pressing and still not ready for mass output. (59)

Nanotechnology-Based Orodispersible Formulations:

Putting nanotech into ondansetron ODTs brings real advantages in how it's made. Tiny particles built with stuff like Eudragit® E100 or chitosan wrap around the medicine - this hides bitter taste thanks to a shield-like coating. They also help the drug mix better with fluids by keeping it stable in an amorphous form. Instead of one quick burst, you get two-phase action: fast effect in the mouth followed by slower release in the gut. On top of that, these carriers guard against damage caused by damp air. (60,61)

Recent research into tiny particles for making lopinavir and ritonavir easier to take showed promise - this method could work well for ondansetron too. Using Eudragil® E PO shells helped trap the medicine, so it stayed stable without forming crystals. The fast-dissolving tablets broke apart in just under 7 seconds, give or take a bit. Almost all of the drug got packed inside - over 98%, actually. Tests with an artificial taste sensor proved the bitter flavor was much less noticeable. Compared to regular pills, these new ones got more medicine into the body. Since both

cases deal with bad-tasting meds, this approach fits right in for creating better ondansetron tablets. (62)

A different trial used a Box–Behnken setup to make fast-dissolving tablets with silymarin nanoparticles - these released 98.5% of the medicine in just 15 minutes when 5% crospovidone was added. Using smart design methods alongside nano-sized particles shows a working strategy that could easily fit into making similar ondansetron tablets. (63)

Artificial Intelligence and Machine Learning for Formulation Optimization:

AI and machine learning are new helpers that could make creating ondansetron ODTs way faster - cutting down how much we depend on slow, hands-on testing. Instead of guessing, these systems guess the best ingredients and their amounts, along with settings like pressure or heat during production; they also fine-tune steps such as mixing and drying. All this happens while still hitting key goals: tablets break apart in under half a minute, have strength between 8–15 kP, lose less than 1% when handled, and deliver more than 90% of the medicine within quarter of an hour. (63)

Artificial neural networks work better when paired with genetic algorithms to fine-tune ondansetron ODT recipes. These networks learn from old lab data, mapping how ingredients affect key product traits; once trained, they plug into genetic systems that test tons of mix options in simulation instead of real experiments. That way, researchers find top-performing blends - ones that dissolve quickly but stay strong enough to handle. (64)

A deep learning project tested 1,983 fast-dissolving tablet mixes, hitting 73% precision on melt time forecasts while nailing hardness predictions at 99%, thanks to a 12-layer neural setup - slashing lab trial demands. Using similar smart tech for ondansetron tablets might speed things up: it helps pick better inactive ingredients, auto-adjusts rapid-break additives based on how the drug reacts to humidity, guesses shelf life without lengthy stress tests, cutting down creation time from nearly two years to just half a year or nine months. (63,64)

Quality-by-Design (QbD) Integration with Emerging Technologies:

Folks working on future ondansetron ODTs will lean into quality-by-design ideas - this means really getting how mix ingredients and making steps shape key traits. Think stuff like drug crystal size, form type, or how wet fillers are matters big time. They'll also pin down vital production settings: blend times, press strength, heat levels. Using planned test runs helps see what changes do. From that, they build a safe zone where every batch turns out right. Pairing smart algorithms with these methods speeds things up - models guess outcomes early, cut lab grind, yet boost reliability.(63,64)

Future Regulatory and Clinical Pathways:

Regulatory groups like the FDA and EMA are pushing faster routes to approve custom 3D-printed meds shaped with AI help - thanks partly to how Spritam® paved the way. Next-gen ondansetron ODTs will likely use smart algorithms to fine-tune recipes under QbD rules, mix in tailor-made printed pills, apply nano-carriers that boost shelf life and hide bitter flavors, while tapping ML models for live monitoring during production. These upgrades tackle today's ODT bottlenecks, steering drug design into a smarter, more personal era focused squarely on patients. (59,63–65)

CONCLUSION

The research suggests ondansetron ODTs are a solid step forward for treating nausea and vomiting from chemo or surgery - thanks to quick breakdown and uptake in the body. Thanks to better formula techniques, including smart disintegrant use, improved flavor covering tricks, along with freeze-drying or melted layer production, these tablets last longer, taste better, hold up well; which boosts real-world results while making them easier to take.

Pharmacokinetic studies suggest ondansetron ODTs work just like standard tablets - only they hit peak blood levels quicker, which tends to boost real-world performance. Research across adults, kids, and unique patient groups reveals ODTs often outperform traditional forms, thanks to easier use, stronger approval from patients, along with more consistent dosing habits; this shift typically leads to healthier results and a noticeable lift in daily living.

Safety info shows keeping an eye on heart rhythm changes linked to dosage is key - especially when treating older adults or those with liver issues. Fixing mineral imbalances goes hand-in-hand with that effort. Groups like the FDA and EMA took this seriously, tweaking rules and package details so usage stays safe. These updates also help more people get hold of dissolvable ondansetron tablets without hassle.

Market trends show a quick rise in need for medicines made around patients' needs, while ODTs are turning out useful in cancer support by boosting compliance and cutting down delivery hassles. Cost studies highlight mixed results - though they're pricier upfront, less strain on health systems and better treatment success can help offset expenses. Still, access is tough in low-resource areas, so work must go on to lower prices and improve distribution networks.

Folks looking ahead need to tackle how dampness messes with ODTs - plus getting them made big-scale isn't easy either. New tricks like printing layer by layer, tiny-sized medicine mixes, or smart systems that tweak formulas could totally change how we make ondansetron tablets you dissolve fast. Using those tools might let doctors hand out doses built just for one person, get meds into the body better, even check quality while it's happening - kinda like custom care when nausea hits hard. Mix-in pills that pair ondansetron with other sickness fighters - or helpers - also crank up the power when fighting symptoms many ways at once.

REFERENCES

1. Tyers MB, Freeman AJ. Mechanism of the Anti-Emetic Activity of 5-HT₃ Receptor Antagonists. Oncology. 1992;49(4):263–8.
2. Gadhe A, Pustake B, Shinde M, Korhale R, Gharge V. Development and Evaluation of Ondansetron Orally Disintegrating Tablets. British Journal of Pharmacy. 2018 Dec 17;3(1).
3. Zhang Q, Jianjun Z, Meng W, Zheng Z, Junrong Z, Yubing Z. Pharmacokinetics and bioavailability study of two ondansetron oral soluble film formulations in fasting healthy male Chinese volunteers. Drug Des Devel Ther. 2015 Aug;4621.
4. Hegde H, Yaliwal V, Annigeri R, Sunilkumar K, Rameshkumar R, Rao Pr. Efficacy of orally disintegrating film of ondansetron versus intravenous ondansetron in prophylaxis of postoperative nausea and vomiting in patients undergoing elective gynaecological laparoscopic procedures: A prospective randomised, double-blind placebo-controlled study. Indian J Anaesth. 2014;58(4):423.

5. R. Gosai A, B. Patil S, K. Sawant K. Formulation and Evaluation of Oro Dispersible Tablets of Ondansetron Hydrochloride by Direct Compression using Superdisintegrants. International Journal of Pharmaceutical Sciences and Nanotechnology. 1970 Jan 1;1(1):106–11.
6. KUMAR A, SAHARAN VA. A Comparative Study of Different Proportions of Superdisintegrants: Formulation and Evaluation of Orally Disintegrating Tablets of Salbutamol Sulphate. Turk J Pharm Sci. 2017 Apr 1;14(1):40–8.
7. Anirudh Srivatsa.P, Harish.G, Pragath kumar.B, Debjit Bhowmik DuraivelS, Duraivel.S. Effect of Super Disintegrants on Formulation of Ondansetron HCL Immediate Release Tablets by Direct Compression method. International Journal of Pharmaceutical and Clinical Research . 2012;4(4):61.
8. P. R. Adavadkar, S. R. Rupvate, S. S. Ukhade, V. P. Rawal. A Systematic Overview On: Orodispersible Tablets . International Journal of Pharmaceutical Research and Applications. 2022;7(4):345–52.
9. Khan S, Kataria P, Nakhat P, Yeole P. Taste masking of ondansetron hydrochloride by polymer carrier system and formulation of rapid-disintegrating tablets. AAPS PharmSciTech. 2007 Jun;8(2):E127–33.
10. Pradip Sonwane M, Dr. Bhusnure O.G, Gaikwad V, Sayyed Sarfaraz Ali, Garkal Atul, Kamble Santosh. A REVIEW - FORMULATION & DEVELOPMENT OF ORODISPERSIBLE TABLET . Indo American Journal of Pharmaceutical Research. 2015 Dec 31;5(12).
11. Divya Jadhao, Pooja Gavanda, Dr. K. R. Biyani. Review On Orodispersible Tablets: Opportunity & Challenges . INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES . 2025;3(3):650–61.
12. Khan S, Kataria P, Nakhat P, Yeole P. Taste masking of ondansetron hydrochloride by polymer carrier system and formulation of rapid-disintegrating tablets. AAPS PharmSciTech. 2007 Jun;8(2):E127–33.
13. Khan S, Kataria P, Nakhat P, Yeole P. Taste masking of ondansetron hydrochloride by polymer carrier system and formulation of rapid-disintegrating tablets. AAPS PharmSciTech. 2007 Jun;8(2):E127–33.
14. Subedi SR, Poudel BK, Budhathoki U, Budhathoki U. Taste Masking and Formulation of Ondansetron Hydrochloride Mouth Dissolving Tablets . International Journal of Drug Delivery Technology . 2014;05(03):104–10.
15. Aksu B, Yegen G, Purisa S, Cevher E, Ozsoy Y. Optimisation of Ondansetron Orally Disintegrating Tablets Using Artificial Neural Networks. Tropical Journal of Pharmaceutical Research. 2014 Oct 10;13(9):1374.
16. Mohammad Ali Shahtalebi, Majid Tabbakhian, Sina Koosha. Formulation and evaluation of orally disintegrating tablet of ondansetron using natural superdisintegrant . Journal of HerbMed Pharmacology. 04(03):102–9.
17. Griddine A, Bush JS. Ondansetron. xPharm: The Comprehensive Pharmacology Reference [Internet]. 2023 Feb 15 [cited 2025 Nov 10];1–6. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499839/
18. Zhang Q, Jianjun Z, Meng W, Zheng Z, Junrong Z, Yubing Z. Pharmacokinetics and bioavailability study of two ondansetron oral soluble film formulations in fasting healthy male Chinese volunteers. Drug Des Devel Ther. 2015 Aug;4621.

19. Priyank Patel, andip Makwana, Urvish Jobanputra, Mihir Ravat. Sublingual route for the systemic delivery of Ondansetron. Int J Drug Dev & Res,. 2011;04(03):36–44.
20. HA H, A S, GS K, S J. Comparison of oral olanzapine versus oral ondansetron for prevention of postoperative nausea and vomiting in female patients undergoing laparoscopic cholecystectomy under general anaesthesia. Journal of Medical and Scientific Research. 2024 Jan 3;12(1):21–5.
21. Kalasree M, Vasantha Kumar K, Vishwatha Hari Baskar, Parthiban Nagaraj, Ashokkumar Manoharan, Prabhu T. A Comparative Study of The Efficacy of Ondansetron, Dexamethasone, And Ondansetron-Dexamethasone Combination for Postoperative Nausea and Vomiting Prophylaxis in Patients Undergoing Laparoscopic Surgeries. European Journal of Cardiovascular Medicine. 2024;14(06):54–9.
22. Ashour AM. The preventive effects of ondansetron on chemotherapy-induced nausea and vomiting in adult cancer patients: systematic review from ClinicalTrials.gov. Front Pharmacol. 2023 Nov 23;14.
23. Gralla R, Lichinitser M, Van der Vegt S, Sleeboom H, Mezger J, Peschel C, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Annals of Oncology. 2003 Oct;14(10):1570–7.
24. Choudhary A, Parashar V. Comparative study of palonosetron and ondansetron in prevention of post operative nausea and vomiting after laparoscopic gynaecological surgeries. Indian Journal of Clinical Anaesthesia. 2020 May 28;7(1):59–63.
25. Ondansetron 4 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc) | 5222 [Internet]. [cited 2025 Nov 10]. Available from: https://www.medicines.org.uk/emc/product/5222/smpc
26. Wagner DS, Gauger V, Chiravuri D, Faust K. Ondansetron oral disintegrating tablets for the prevention of postoperative vomiting in children undergoing strabismus surgery. Ther Clin Risk Manag. 2007 Aug;3(4):691–4.
27. Ahmad M, Rawat A, Farrukh S, Haq I, Kumar Mandal A, Syed A, et al. Comparative Analysis of Oral Ondansetron, Metoclopramide, and Domperidone for Managing Vomiting in Children With Acute Gastroenteritis. Cureus. 2023 Oct 24;
28. Barot KS, Vaghasiya KN, Suhagiya GH, Singh AP, Nadeem S, Qureshi AN, et al. Comparing the Efficacy of Ondansetron, Domperidone, and Metoclopramide in Treating Vomiting in Pediatric Patients With Acute Gastroenteritis: A Network Meta-Analysis. Cureus. 2024 Aug 27;
29. Hegde H, Yaliwal V, Annigeri R, Sunilkumar K, Rameshkumar R, Rao Pr. Efficacy of orally disintegrating film of ondansetron versus intravenous ondansetron in prophylaxis of postoperative nausea and vomiting in patients undergoing elective gynaecological laparoscopic procedures: A prospective randomised, double-blind placebo-controlled study. Indian J Anaesth. 2014;58(4):423.
30. Mistry P, Batchelor H. Evidence of acceptability of oral paediatric medicines: a review. Journal of Pharmacy and Pharmacology. 2017 Apr 1;69(4):361–76.
31. Cohen IT, Joffe D, Hummer K, Soluri A. Ondansetron Oral Disintegrating Tablets: Acceptability and Efficacy in Children Undergoing Adenotonsillectomy. Anesth Analg. 2005 Jul;101(1):59–63.

32. Singh K, Jain A, Panchal I, Madan H, Gupta A, Sharma A, et al. Ondansetron-induced QT prolongation among various age groups: a systematic review and meta-analysis. The Egyptian Heart Journal. 2023 Jul 3;75(1):56.
33. FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran) | FDA [Internet]. [cited 2025 Nov 11]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-information-regarding-qt-prolongation-ondansetron-zofran
34. Ondansetron for intravenous use: dose-dependent QT interval prolongation - GOV.UK [Internet]. [cited 2025 Nov 11]. Available from: https://www.gov.uk/drug-safety-update/ondansetron-for-intravenous-use-dose-dependent-qt-interval-prolongation
35. Freedman SB, Adler M, Seshadri R, Powell EC. Oral Ondansetron for Gastroenteritis in a Pediatric Emergency Department. New England Journal of Medicine. 2006 Apr 20;354(16):1698–705.
36. Yang F, Xu L, Lang X, Feng X. A real-world safety signal detection study of ondansetron based on FAERS reports from 2014 to 2024. Sci Rep. 2025 Aug 26;15(1):31339.
37. Colvin L, Gill AW, Slack-Smith L, Stanley FJ, Bower C. Off-label use of ondansetron in pregnancy in Western Australia. Biomed Res Int. 2013;2013.
38. Griddine A, Bush JS. Ondansetron. xPharm: The Comprehensive Pharmacology Reference [Internet]. 2023 Feb 15 [cited 2025 Nov 11];1–6. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499839/
39. Freedman SB, Adler M, Seshadri R, Powell EC. Oral Ondansetron for Gastroenteritis in a Pediatric Emergency Department. New England Journal of Medicine. 2006 Apr 20;354(16):1698–705.
40. Fda, Cder. Draft Guidance on Ondansetron Hydrochloride. 2024 [cited 2025 Nov 11]; Available from: http://www.accessdata.fda.gov/scripts/cder/dissolution/.
41. Medicines Agency E. List of nationally authorised medicinal products. [cited 2025 Nov 11]; Available from: www.ema.europa.eu/contact
42. Orodispersible Tablets Market Size, Share and Forecast to 2034 [Internet]. [cited 2025 Nov 11]. Available from: https://www.insightaceanalytic.com/report/orodispersible-tablets-market/1916
43. Orodispersible Tablets Market Size & Forecast, 2025-2032 [Internet]. [cited 2025 Nov 11]. Available from: https://www.coherentmarketinsights.com/market-insight/orodispersible-tablets-market-5745
44. Mr. Abhishek Arun Rathod, Dr. Pankaj M. Pimpalshende. Orodispersible Tablets in Modern Pharmaceutical Sciences: An Insight into Preparation and Clinical Applications. International Journal of Advanced Research in Science, Communication and Technology. 2025;04(05).
45. Osman AAM, Elhassan MMA, AbdElrahim BHA, Ahmed FHA, Yousif JBH, Ahmed MAM, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan. J Glob Oncol. 2018 Dec;(4):1–9.
46. Jiang C, Yabroff KR, Nipp RD, Han X, Hu X, Liao JM, et al. Costs and Access Barriers to Ondansetron in the US. JAMA Netw Open. 2024 Nov 7;7(11):e2443978.
47. Ballatori E, Roila F, Berto P, De Angelis V, Neri C, Olivieri A, et al. Cost and Cost-Effectiveness Analysis of Ondansetron Versus

Metoclopramide Regimens†. Pharmacoeconomics. 1994 Mar;5(3):227–37.
48. Cost Effectiveness of Ondansetron and Metoclopramide in the Treatment of Post-Operative Nausea and Vomiting in Patients Undergoing Elective Surgery. [cited 2025 Nov 11]; Available from: http://www.rees-france.com
49. Fatima SS, Zafar F, Ali H, Raees F, Naqvi GR, Alam S, et al. Development and characterisation of orally disintegrating flurbiprofen tablets using SeDeM-ODT tool. PLoS One [Internet]. 2024 Oct 1 [cited 2025 Nov 11];19(10 October). Available from: https://drug-dev.com/formulation-forum-orally-disintegrating-tablets/
50. Snehal Dhewale, Bhagwan Kale, Vaishanvi Chivte, Rutuja Dhakne, Dr. Santosh Shep. The preparation of orodispersible tablet & study effect of processing condition on Tablet .
51. Fatima SS, Zafar F, Ali H, Raees F, Naqvi GR, Alam S, et al. Development and characterisation of orally disintegrating flurbiprofen tablets using SeDeM-ODT tool. PLoS One [Internet]. 2024 Oct 1 [cited 2025 Nov 11];19(10 October). Available from: https://drug-dev.com/formulation-forum-orally-disintegrating-tablets/
52. Ghourichay MP, Kiaie SH, Nokhodchi A, Javadzadeh Y. Formulation and Quality Control of Orally Disintegrating Tablets (ODTs): Recent Advances and Perspectives. Biomed Res Int. 2021 Jan 24;2021(1).
53. T.Ethiraj, V.Ganesan, S.Gokula Manmohan Singh, G.Bommi Alias Aishwarya, T.Karthick, J.Sathish, et al. Comparative Studies on Oral Dispersible Tablet of Ondansetron Hydrochloride Marketed Products. International Journal of Pharmaceutical Research and Applications. 08(06):245–50.
54. FORMULATION FORUM - Orally Disintegrating Tablets [Internet]. [cited 2025 Nov 16]. Available from: https://drug-dev.com/formulation-forum-orally-disintegrating-tablets/
55. Monika Tomar, Amit Raj Sinha. Design, Characterization and Evaluation of Quick Dissolving Matrix BARETab® ODT Tablet In Ondansetron Formulation. 2020;08(05).
56. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research. Journal of Clinical Oncology. 1997 Jan;15(1):124–30.
57. Balachandar S, Parthasarathy S, Sripriya R, Kulandayyan S. Efficacy of palonosetron in comparison with other 5-HT3 antagonist drugs in preventing postoperative nausea and vomiting after otorhinolaryngological surgeries: A meta-analysis. Indian Journal of Clinical Anaesthesia. 2025 Jan 28;12(1):4–14.
58. Ghourichay MP, Kiaie SH, Nokhodchi A, Javadzadeh Y. Formulation and Quality Control of Orally Disintegrating Tablets (ODTs): Recent Advances and Perspectives. Biomed Res Int. 2021 Jan 24;2021(1).
59. Vaibhav Shikare, Kharate AB, Patokar RG, Pawar AR, Chavan GG. Advancements in 3D Printing for Pharmaceutical Applications: A Systematic Review. Int J Multidiscip Eng Curr Res (IJMEC). 2025;10(2):43-52
60. Kotame RN, Daniel K. Formulation, Development and Optimization of Silymarin Loaded Nanoparticle Orodispersible Tablets for its Anti-inflammatory Activity. INTERNATIONAL JOURNAL OF DRUG DELIVERY TECHNOLOGY. 2024 Sep 25;14(03):1722–7.
61. Ms. Radhika N Kotame, Dr. Kratika Daniel. In Vitro -Vivo Study Of Orodispersible Tablet Of

Silymarin Based Nanoparticle For Anti-Inflammatory Characterization. 2025;14(28).
62. Deng Y, Shen L, Yang Y, Shen J. Development of nanoparticle-based orodispersible palatable pediatric formulations. Int J Pharm. 2021 Mar;596:120206.
63. Momeni M, Afkanpour M, Rakhshani S, Mehrabian A, Tabesh H. A prediction model based on artificial intelligence techniques for disintegration time and hardness of fast disintegrating tablets in pre-formulation tests. BMC Med Inform Decis Mak. 2024 Mar 27;24(1):88.
64. Kisanrao Bibhishan Mundhe, Dr. Chitra V, Dr. Parani Madasamy. Optimization of Tablet Formulation using Artificial Neural Networks and Genetic Algorithm. 2024;53(03).
65. Serrano DR, Kara A, Yuste I, Luciano FC, Ongoren B, Anaya BJ, et al. 3D Printing Technologies in Personalized Medicine, Nanomedicines, and Biopharmaceuticals. Pharmaceutics. 2023 Jan 17;15(2):313.

HOW TO CITE: Rani Ade*, Vaishnavi Tajne, Dr. Avinash Jiddewar, Pradip More, A Comprehensive Review on Ondansetron Orodispersible Tablets, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 12, 2353-2375 https://doi.org/10.5281/zenodo.17934205